Patients with NSCLC and EGFR mutations or ALK or ROS1 gene rearrangement are eligible for first-line targeted therapy with the respective appropriate drug, resulting in greatly improved clinical outcomes [4,5,6]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.